4-OHC	4-Hydroxycyclophosphamide
AC	Doxorubicin plus 4-Hydroxycyclophosphamide
AC-T	Anthracycline/Cyclophosphamide-Taxane chemotherapy
ATCC	American Type Culture Collection
BC	Breast Cancer
BME	Basement Membrane Extract
Cmax	Maximum Plasma Concentration
CR-like	Complete Response-like
DFS	Disease-Free Survival
DOXO	Doxorubicin
DTX	Docetaxel
ECM	Extracellular matrix
EPI	Epirubicin
FBS	Fetal Bovine Serum
FDR	False Discovery Rate
GDSC	Genomics of Drug Sensitivity in Cancer
GR	Growth Rate
GR50	Concentration associated with 50% growth-rate inhibition
GRmax	Maximum growth-rate effect
HER2	Human Epidermal Growth Factor Receptor 2
HR	Hormone Receptor
IC50	Half-Maximal Inhibitory Concentration
IDA	Independent Drug Action
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
OS	Overall Survival
PD-like	Progressive Disease-like
PDO	Patient-Derived Organoid
PCE	Probability of Chemotherapeutic Efficacy
PR-like	Partial Response-like
PTX	Paclitaxel
RCB	Residual Cancer Burden
RECIST	Response Evaluation Criteria in Solid Tumors
SD-like	Stable Disease-like
STR	Short Tandem Repeat
TNBC	Triple-Negative Breast Cancer